Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03545425 · ClinicalTrials.gov registry record
Fox BioNet Project: LRRK2-002
A clinical trial of Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- Completed
- Registry status
- 114
- Enrollment target
- 5
- Study locations
NCT03545425 is a study of Parkinson Disease that has completed, run by Michael J. Fox Foundation for Parkinson's Research. The registered enrollment target is 114 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT03545425, a study of Parkinson Disease, has completed, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- COMPLETED
- Registry status
- 114 participants
- Enrollment target
- 5
- Study locations
Study Summary
The overall objective of this study is to determine whether LRRK2 kinase activity and/or mitochondrial DNA (mtDNA) damage could serve as potential biomarkers in PD.
Conditions Studied
Interventions
- PROCEDURE Biofluid samplings
Study Locations (5)
Florida
- Charles E. Schmidt College of Medicine, Florida Atlantic University - Boca Raton
Illinois
- Northwestern University - Chicago
New York
- Columbia University Medical Center - New York
Oregon
- Oregon Health and Sciences University - Portland
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2018-05-16 |
| Est. Completion | 2020-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03545425
The ClinicalTrials.gov registry entry for NCT03545425 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The listed sponsor is Michael J. Fox Foundation for Parkinson's Research, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Biofluid samplings is the first listed.
NCT03545425 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Florida, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT03545425 about?
NCT03545425 is a clinical study titled "Fox BioNet Project: LRRK2-002". The overall objective of this study is to determine whether LRRK2 kinase activity and/or mitochondrial DNA (mtDNA) damage could serve as potential biomarkers in PD.
What is the current status of trial NCT03545425?
This trial is currently completed. The enrollment target is 114 participants. The study started on 2018-05-16. Estimated completion is 2020-04-30.
What conditions does trial NCT03545425 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT03545425?
The interventions under investigation include: Biofluid samplings (PROCEDURE).
Who is sponsoring clinical trial NCT03545425?
This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03545425 being conducted?
This trial has 5 study locations across Florida, Illinois, New York, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.